ESMO 2022 Bladder Cancer

Viewing 1-16 of 16 articles

ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers

ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial

ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial

ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial

ESMO 2022: Disease-Free Survival and Distant Metastasis-Free Survival as Surrogates for Overall Survival in Adjuvant Treatment of Muscle-Invasive Bladder Cancer

ESMO 2022: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results from Patients with ≥12 Months of Treatment in JAVELIN Bladder 100

ESMO 2022: Prevalence of PD-L1 High Expression in Advanced Urothelial Carcinoma (aUC): Results from the PREVAIL Prospective Cohort Study

ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress)

ESMO 2022: A Discussion on Radiation Therapy Before Radical Cystectomy combined with Immunotherapy in Locally Advanced Urothelial Carcinoma, First Results from BladderPath, and BC2001 and BCON Randomised Trials

ESMO 2022: First Results from BladderPath: A Randomised Trial of MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer

ESMO 2022: RACE IT - A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder

ESMO 2022: Hypoxic Bladder Cancers Have a Poorer Outcome Following Hypofractionated Vs Conventionally Fractionated Radiotherapy in the BC2001 and BCON Randomised Trials

ESMO 2022: PD-L1 Expression on Immune Cells by SP142 Co-Localizes with Dendritic Cells and Is Associated with Improved OS with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer

ESMO 2022: Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?

ESMO 2022: Genomic Biomarkers in Peripheral Blood From Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma